Follow us on
Welcome Guest! You are here: Home » Health
Govt caps coronary stent prices to check unethical practices

Tuesday February 14, 2017 2:30 PM, & Agencies

Coronary stent

New Delhi:
The government has reduced prices of coronary stents by up to 400 per cent, capping them at Rs 7,260 for bare metal ones and Rs 29,600 for the drug eluting variety.

The National Pharmaceuticals Pricing Authority (NPPA) under Ministry of Chemicals and Fertilizers Department of Pharmaceuticals in a notification issued Monday said in public interest, it has fixed the ceiling price of bare metal stents at 7,260 and that of drug eluting stents and bioresorbable vascular scaffold (BVS)/biodegradable stents at Rs 29,600.

"The NPPA in its Authority Meeting held on 13th February 2017, after duly examining in detail and considering all available information/data and all relevant options for price fixation of Coronary Stents, under present extraordinary circumstances of a failed and exploitative market system has decided that it is immediately necessary to fix ceiling prices of Coronary Stents, in order to protect public interest", it said.

A coronary stent is a tube-shaped device placed in the arteries that supply blood to the heart. It keeps the arteries open in the treatment of coronary heart diseases.

The maximum retail cost of a stent currently ranges from Rs 25,000 to Rs 1.98 lakh.

Data at NPPA website showed that hospitals make the maximum profits on stents, with trade margin going up to 654 per cent.

Citing the reasons for its order, NPPA said: " was found that huge unethical markups are charged at each stage in the supply chain of coronary stents resulting in irrational, restrictive and exorbitant prices in a failed market system driven by information asymmetry between patients and doctors pushing patients to financial misery".

Under such extraordinary circumstances, there is an urgent necessity, in public interest, to fix ceiling price of coronary stents to bring respite to the patients, it added.

The government had included coronary stents in the national list of essential medicines (NLEM), 2015 in July 2016 and in the first Schedule of the Drug Prices Control Order (DPCO), 2013 in December 2016.



Share this page
 Post Comments
Note: By posting your comments here you agree to the terms and conditions of